Status:

UNKNOWN

Study of Optimal Treatment Plan in Hypertensives With Anti-AT1-Receptor Autoantibody

Lead Sponsor:

Huazhong University of Science and Technology

Conditions:

Hypertension

Eligibility:

All Genders

18-80 years

Phase:

PHASE4

Brief Summary

The autoantibodies against AT1 receptor (ATR-AA), behaving like an agonist were detected in patients with hypertension. ATR-AA which can blocked by ARB may play a role in the pathogenesis of hypertens...

Eligibility Criteria

Inclusion

  • Hypertension (2 grade)

Exclusion

  • Secondary hypertension
  • Known sensitivity or intolerance to an angiotensin II receptor antagonist or ACE inhibitor
  • Pregnancy

Key Trial Info

Start Date :

Trial Type :

INTERVENTIONAL

End Date :

December 1 2006

Estimated Enrollment :

600 Patients enrolled

Trial Details

Trial ID

NCT00360763

End Date

December 1 2006

Last Update

August 7 2006

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Department of Cardiology, Wuhan Union Hospital

Wuhan, Hubei, China, 430022